Barclays lowered the firm’s price target on 10x Genomics to $21 from $24 and keeps an Overweight rating on the shares. Investor sentiment towards the life science tools and diagnostics group has improved since the nadir of Q2 as the end markets are in a better place to start Q3 than they were last quarter, the analyst tells investors in a research note. Heading into the Q3 report, Barclays likes names with “idiosyncratic growth drivers” that will lead to core growth at the high end or above the rest of peers. It also likes stocks with multiples trading within historical ranges that can give valuation support for more upside and a potential breakout of the trading range.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Cathie Wood’s ARK Investment buys 1.15M shares of 10x Genomics today
- Delta reports mixed Q3, Domino’s reports earnings beat: Morning Buzz
- Morning Movers: GXO Logistics gains following report of potential sale
- 10x Genomics price target lowered to $20 from $32 at Canaccord
- Closing Bell Movers: 10x Genomics falls 27% on’cautious’ customer spending
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue